Stocks
Moderna and Merck's Melanoma Vaccine Trial Yields Promising Results
US pharmaceutical firms Merck and Moderna have announced encouraging results from a trial of their experimental vaccine against melanoma.
The vaccine, called intismeran autogene, showed statistically significant and clinically meaningful improvements for skin cancer patients when used with Merck's Keytruda treatment.
This represents the first positive Phase 3 readout for an individualised neoantigen therapy (INT) and for an mRNA-based cancer therapy.
Moderna's CEO Stephane Bancel said, 'For many years, the idea of creating an mRNA treatment designed specifically for an individual patient's cancer was aspirational. We are now helping turn that vision into a reality.'